DrugPatentWatch Database Preview
Drugs in Development Information for Mapracorat
» See Plans and Pricing
What is the drug development status for Mapracorat?
Mapracorat is an investigational drug.
There have been 12 clinical trials for Mapracorat.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2012.
The most common disease conditions in clinical trials are Inflammation, Cataract, and Eczema. The leading clinical trial sponsors are Bausch & Lomb Incorporated, Bayer, and [disabled in preview].
There are twenty-three US patents protecting this investigational drug and two hundred and sixty-five international patents.
Summary for Mapracorat
US Patents | 23 |
International Patents | 265 |
US Patent Applications | 81 |
WIPO Patent Applications | 51 |
Japanese Patent Applications | 12 |
Clinical Trial Progress | Phase 3 (2012-07-01) |
Vendors | 17 |
Recent Clinical Trials for Mapracorat
Title | Sponsor | Phase |
---|---|---|
1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat | Bayer | Phase 1 |
Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days | Bausch & Lomb Incorporated | Phase 1 |
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery | Bausch & Lomb Incorporated | Phase 3 |
Clinical Trial Summary for Mapracorat
Top disease conditions for Mapracorat
Top clinical trial sponsors for Mapracorat
US Patents for Mapracorat
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Mapracorat | Start Trial | Kinase inhibitors | Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB) | Start Trial |
Mapracorat | Start Trial | Self-assembly of therapeutic agent-peptide nanostructures | Ohio State Innovation Foundation (Columbus, OH) Trustees of Boston University (Boston, MA) | Start Trial |
Mapracorat | Start Trial | Kinase inhibitors | Respivert Limited (N/A) Topivert Pharma Limited (London, GB) | Start Trial |
Mapracorat | Start Trial | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | NICOX OPHTHALMICS, INC. (Fort Worth, TX) | Start Trial |
Mapracorat | Start Trial | Uses of 6-aminohexanoic acid to manage bleeding conditions | Emory University (Atlanta, GA) | Start Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Mapracorat
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Mapracorat | Australia | AU2017245888 | 2036-04-06 | Start Trial |
Mapracorat | Brazil | BR112018067552 | 2036-04-06 | Start Trial |
Mapracorat | Canada | CA3015978 | 2036-04-06 | Start Trial |
Mapracorat | China | CN109071505 | 2036-04-06 | Start Trial |
Mapracorat | Eurasian Patent Organization | EA201892213 | 2036-04-06 | Start Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |